ALXO — ALX Oncology Holdings Share News
0.000.00%
Last trade - 00:00Brief: Alx Oncology Reports First Quarter 2023 Financial Results
Brief: ALX Oncology Q1 loss from operations USD 32.203 million
Brief: Alx Oncology Announces First Patient Dosed In Phase 2 Investigator-Sponsored Trial Of Evorpacept In Patients With Ovarian Cancer
ALX Oncology Holdings Inc expected to post a loss of 80 cents a share - Earnings Preview
Brief: ALX Oncology, Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed In I-SPY-P1 Trial
Brief: Alx Oncology Holdings Inc - Co And Its Subsidiaries Have Cash In Operating Accounts With Svb
Brief: Alx Oncology Announces First Patient Dosed In The I-SPY-P1 Trial In Breast Cancer
U.S. RESEARCH ROUNDUP- Ameresco, Bioxcel Therapeutics, Roblox
ALX Oncology Holdings Inc reports results for the quarter ended in December - Earnings Summary
Brief: ALX Oncology Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: ALX Oncology Posts Q4 net loss USD30.709 million
ALX Oncology Holdings Inc expected to post a loss of 89 cents a share - Earnings Preview
Brief: Alx Oncology Announces First Patient Dosed In Aspen-07, A Phase 1 Study Of Evorpacept For The Treatment Of Patients With Urothelial Cancer
ALX Oncology rises on positive initial data from blood cancer drug trial
Brief: Alx Oncology Holdings Inc - Increased Size Of Board Of Directors From Seven To Eight Directors In Connection With Garland's Appointment
Brief: Alx Oncology Appoints Scott Garland To Board Of Directors
ALX Oncology Holdings Inc reports results for the quarter ended in September - Earnings Summary
Brief: ALX Oncology Reports Third Quarter 2022 Financial Results, Provides Clinical Development, Operational Highlights
ALX Oncology Holdings Inc expected to post a loss of 77 cents a share - Earnings Preview